CBD as a neuroprotectant: what is this property of cannabidiol?
CBD as a neuroprotectant has been studied by various research groups. In this post we explain these properties of CBD in the brain and the possible applications for which it is being studied. Please remember that this is an informational article and is not intended to prevent, diagnose or treat any disease.
Neuroprotective effect of CBD
Cannabidiol (CBD) is one of the phytocannabinoids found in the cannabis plant, known for its many health benefits and its non-psychoactive properties. Among its vast range of therapeutic uses, recent studies have shown that CBD can also act as a neuroprotectant.
What does it mean when we say CBD is neuroprotective?
CBD is a phytocannabinoid with the ability to protect brain cells from damage, degeneration or malfunction. It provides this protection through the different effects cannabidiol has on neurons:
Anti-inflammatory
CBD protects the nervous system thanks to its potent anti-inflammatory action, since one of the most common features of neurological conditions is chronic inflammation. CBD reduces inflammation in the body by dampening the local immune response, acting as an antioxidant and reducing the release of pro-inflammatory cytokines that perpetuate the inflammatory process (1, 2, 3, 4). Likewise, CBD has been shown to protect brain cells from apoptosis, or cell death caused by inflammation, by reducing cellular stress (5, 6). Read more in our post on CBD as an anti-inflammatory.
Neurogenesis
Neurogenesis is the process by which new functional neurons are generated in the brain. This process is disrupted by various neurological diseases. In studies with laboratory animals, CBD has been shown to stimulate the formation of new neurons in the hippocampus (7, 8), a brain region linked to memory and learning. Neurogenesis is part of brain plasticity, the capacity of neural networks to change, adapt or reorganise, whether as a result of development, a change of environment, ageing or disease.
Neuronal plasticity is affected in diseases such as dementia, schizophrenia and epilepsy (9, 10). And since the endocannabinoid system partly contributes to controlling neurogenesis, palliative treatment with CBD as a neuroprotectant could be of great help.
Antioxidant
CBD can interrupt the action of free radicals by capturing them or transforming them into less harmful radicals (11), and can even reduce their production (12, 13, 14). As a neuroprotectant, CBD may lessen the impact of the oxidative stress resulting from neurodegenerative diseases, head injury, chronic stress and other neuronal conditions.
What is oxidative stress? Our tissues contain free radicals (or oxidising agents) that are formed by normal cellular processes. These radicals are usually kept in balance by the action of antioxidant compounds. In many brain diseases or disorders, this balance breaks down, producing oxidative stress. So when free radicals outnumber the antioxidants in the brain, they start to damage the DNA and proteins of neuronal tissue. CBD's antioxidant effect helps to neutralise oxidising agents, reducing oxidative stress damage in the brain.
CBD can also help mitochondrial function. Mitochondria are the organelles that produce energy in cells. Research has suggested that CBD could help repair mitochondrial damage, promoting cellular health (15).
* You may be interested in: How does CBD affect mood? Effects of CBD on neurotransmitters
Potential therapeutic uses of CBD related to its neuroprotective properties
Traumatic brain injuries
It has been shown that CBD as a neuroprotectant could be used to treat traumatic brain injury, since its anti-inflammatory action and antioxidant effect prevent neuronal death and stop seizures from developing (16). It has also been suggested that it may prevent chronic pain from developing after a brain injury (17).
Neurodegenerative diseases
Various studies suggest that, thanks to its anti-inflammatory and antioxidant action, CBD may have beneficial effects in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis.
CBD as a neuroprotectant can be of great help for any neurological disorder that involves an inflammatory process or pain perception. Because CBD interacts with 5-HT1A serotonin receptors and the TRPV1 vanilloid receptor, it can modulate pain perception and mood (18), which also offers an opportunity to bring relief to psychiatric disorders.
How is CBD used for its neuroprotective effects?
There is no dose of CBD as a neuroprotectant as such; there are doses reported for different conditions, in which neuroprotection is one of the effects involved in CBD's therapeutic spectrum. Moreover, talking about a standard dose is complicated, as the effective dose varies from person to person and depending on the condition for which CBD is required as a treatment. For example, the doses of CBD for neurodegenerative diseases such as Alzheimer's or Parkinson's disease used in different studies range from 25 mg/day to 400 mg/day. These doses are given as symptomatic treatment and involve a neuroprotective action of CBD.
As for the dose for traumatic brain injury, the clinical study evaluating its effectiveness in humans, run by the University of Colorado Denver, ended in July 2025 and its results have not yet been published (19). However, in animal models it has been reported that CBD as a neuroprotectant can restore normal levels of neurotransmission, preventing neuronal damage, at doses of 100 mg/kg per day (20).
Remember that any CBD treatment should start with doses lower than the therapeutic ones and then be increased based on the response. You should also bear in mind any possible interactions between CBD and medicines.
Could taking CBD prevent neurodegenerative diseases?
Unfortunately, no. The development of neurodegenerative diseases depends on many factors, such as genetic predisposition, lifestyle and other risk factors. Research has managed to shed light on some of the mechanisms behind these diseases, but there is still no answer when it comes to prevention.
Important considerations about CBD as a neuroprotectant
This article is for information purposes and summarises the current evidence on CBD's impact on the brain, as well as the main ongoing research into its potential applications. These properties of cannabidiol are still being researched. Ask your doctor if you have any questions about your health, and avoid using CBD without professional advice.
Please remember that this is an informational article and is not intended to prevent, diagnose or treat any disease. Its content may complement, but never replace, the diagnosis or treatment of any disease or symptom. Cannactiva products are not medicines. Ask your doctor for more information and before using CBD.
References
- Barichello, T., Ceretta, R. A., Generoso, J. S., Moreira, A. P., Simões, L. R., Comim, C. M., Quevedo, J., Vilela, M. C., Zuardi, A. W., Crippa, J. A., & Teixeira, A. L. (2012). Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. European journal of pharmacology, 697(1-3), 158–164. https://doi.org/10.1016/j.ejphar.2012.09.053
- McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G., & Ross, R. A. (2008). Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Molecular pharmacology, 73(2), 441–450. https://doi.org/10.1124/mol.107.041863.
- Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., & Vogel, Z. (2010). Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. The Journal of biological chemistry, 285(3), 1616–1626. https://doi.org/10.1074/jbc.M109.069294
- Couch, D. G., Tasker, C., Theophilidou, E., Lund, J. N., & O'Sullivan, S. E. (2017). Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clinical science (London, England : 1979), 131(21), 2611–2626. https://doi.org/10.1042/CS20171288
- Mecha, M., Torrao, A. S., Mestre, L., Carrillo-Salinas, F. J., Mechoulam, R., & Guaza, C. (2012). Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell death & disease, 3(6), e331. https://doi.org/10.1038/cddis.2012.71
- Scuderi, C., Steardo, L., & Esposito, G. (2014). Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytotherapy research : PTR, 28(7), 1007–1013. https://doi.org/10.1002/ptr.5095
- Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., & Kempermann, G. (2010). Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell communication and signaling : CCS, 8, 12. https://doi.org/10.1186/1478-811X-8-12
- Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., Galve-Roperh, I., & Guimarães, F. S. (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. The international journal of neuropsychopharmacology, 16(6), 1407–1419. https://doi.org/10.1017/S1461145712001502
- Kempermann, G., & Kronenberg, G. (2003). Depressed new neurons--adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biological psychiatry, 54(5), 499–503. https://doi.org/10.1016/s0006-3223(03)00319-6
- Reif, A., Fritzen, S., Finger, M., Strobel, A., Lauer, M., Schmitt, A., & Lesch, K. P. (2006). Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Molecular psychiatry, 11(5), 514–522. https://doi.org/10.1038/sj.mp.4001791
- Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel, Switzerland), 9(1), 21. https://doi.org/10.3390/antiox9010021
- Baron-Flores, V., Diaz-Ruiz, A., Manzanares, J., Rios, C., Burelo, M., Jardon-Guadarrama, G., Martínez-Cárdenas, M. L. Á., & Mata-Bermudez, A. (2022). Cannabidiol attenuates hypersensitivity and oxidative stress after traumatic spinal cord injury in rats. Neuroscience letters, 788, 136855. https://doi.org/10.1016/j.neulet.2022.136855
- Esposito, G., Scuderi, C., Savani, C., Steardo, L., Jr, De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V., & Steardo, L. (2007). Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. British journal of pharmacology, 151(8), 1272–1279. https://doi.org/10.1038/sj.bjp.0707337
- Ben-Shabat, S., Hanus, L. O., Katzavian, G., & Gallily, R. (2006). New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. Journal of medicinal chemistry, 49(3), 1113–1117. https://doi.org/10.1021/jm050709m
- Ramirez, A., Old, W., Selwood, D. L., & Liu, X. (2022). Cannabidiol activates PINK1-Parkin-dependent mitophagy and mitochondrial-derived vesicles. European journal of cell biology, 101(1), 151185. https://doi.org/10.1016/j.ejcb.2021.151185
- Aychman, M. M., Goldman, D. L., & Kaplan, J. S. (2023). Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries. Frontiers in neurology, 14, 1087011. https://doi.org/10.3389/fneur.2023.1087011
- Belardo, C., Iannotta, M., Boccella, S., Rubino, R. C., Ricciardi, F., Infantino, R., Pieretti, G., Stella, L., Paino, S., Marabese, I., Maisto, R., Luongo, L., Maione, S., & Guida, F. (2019). Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury. Frontiers in pharmacology, 10, 352. https://doi.org/10.3389/fphar.2019.00352
- García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020). Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 10(11), 1575. https://doi.org/10.3390/biom10111575
- University of Colorado, Denver (2023). Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial. U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT05632627
- Santiago-Castañeda, C., Huerta de la Cruz, S., Martínez-Aguirre, C., Orozco-Suárez, S. A., & Rocha, L. (2022). Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery. Pharmaceutics, 14(8), 1609. https://doi.org/10.3390/pharmaceutics14081609
- Katona, S., Kaminski, E., Sanders, H., & Zajicek, J. (2005). Cannabinoid influence on cytokine profile in multiple sclerosis. Clinical and experimental immunology, 140(3), 580–585. https://doi.org/10.1111/j.1365-2249.2005.02803.x
